pramipexole has been researched along with rotenone in 3 studies
| Studies (pramipexole) | Trials (pramipexole) | Recent Studies (post-2010) (pramipexole) | Studies (rotenone) | Trials (rotenone) | Recent Studies (post-2010) (rotenone) |
|---|---|---|---|---|---|
| 1,103 | 219 | 517 | 4,407 | 6 | 1,648 |
| Protein | Taxonomy | pramipexole (IC50) | rotenone (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 8 | |
| NADH-ubiquinone oxidoreductase chain 1 | Bos taurus (cattle) | 0.015 | |
| NADH dehydrogenase [ubiquinone] flavoprotein 1, mitochondrial | Bos taurus (cattle) | 0.0051 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 3.6486 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.87 | |
| Acyl carrier protein, mitochondrial | Bos taurus (cattle) | 0.0051 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Cooper, JM; Gu, M; Iravani, MM; Irvani, M; Jenner, P; King, D; Schapira, AH | 1 |
| Ariga, H; Inden, M; Kitamura, Y; Shibaike, T; Taira, T; Takata, K; Tamaki, A; Taniguchi, T; Yamamoto, A; Yanagida, T; Yasui, H | 1 |
3 other study(ies) available for pramipexole and rotenone
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms.
Topics: 1-Methyl-4-phenylpyridinium; Aconitate Hydratase; Antioxidants; Benzothiazoles; Carbocyanines; Caspase 3; Caspases; Cell Count; Cell Death; Cell Line, Tumor; Cell Survival; Cytochromes c; Dose-Response Relationship, Drug; Drug Interactions; Flow Cytometry; Humans; Jurkat Cells; L-Lactate Dehydrogenase; Mitochondria; Necrosis; Neuroblastoma; Pramipexole; Rotenone; Thiazoles | 2004 |
Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Apoptosis; Benzothiazoles; Cell Line, Tumor; Corpus Striatum; Cytochromes c; Dopamine; Dose-Response Relationship, Drug; Humans; Hydrogen Peroxide; Hydroxyl Radical; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neural Pathways; Neurotoxins; Oxidative Stress; Parkinsonian Disorders; Pramipexole; Proto-Oncogene Proteins c-bcl-2; Rotenone; Substantia Nigra; Uncoupling Agents | 2009 |